Core Viewpoint - The company has recently disclosed its preliminary earnings forecast for the year 2025, indicating a significant expected loss in net profit [2] Financial Performance - The preliminary estimate for the net profit attributable to shareholders for 2025 is projected to be between -58 million and -52 million yuan [2] - The net profit attributable to shareholders after deducting non-recurring gains and losses is expected to range from -56.3 million to -50.3 million yuan [2]

Group 1 - The core viewpoint of the article highlights that the company, ShenZhou Cell, plans to invest approximately 83 million to 87 million yuan in research and development (R&D) by 2025 [2] - The company is currently in a growth phase, and maintaining high R&D investment is essential for its future development, which is a common characteristic among innovative drug development companies [2] - As multiple projects progress into mid-to-late clinical research stages, the company's R&D expenditures are expected to remain elevated [2]

Core Viewpoint - The company Shenzhou Cell indicates that the sales of its product Anjiah will decline significantly in 2025 due to several factors, including medical insurance cost control and substantial price reductions in response to national healthcare policies [1] Group 1: Sales Decline Factors - Medical insurance cost control has led to a decrease in patient usage [1] - Starting from the third quarter of 2025, Anjiah will undergo significant price reductions to align with national healthcare bureau initiatives [1] Group 2: Future Expectations - The company hopes that the price reduction of Anjiah will benefit patients, allowing them to access sufficient medication and improve their survival conditions [1] - The revised "Guidelines for the Treatment of Hemophilia in China (2025 Edition)" emphasizes the importance of preventive treatment and redefines treatment approaches for coagulation disorders [1] - The company anticipates that adult patients will receive better protection similar to that of pediatric patients and hopes that recombinant factor VIII will be treated equally to plasma-derived factor VIII [1]

Core Viewpoint - The article discusses a large-scale healthcare fraud case involving hemophilia patients, pharmaceutical representatives, and private hospitals in Zhejiang, China, highlighting the complexities of healthcare reimbursement policies and the ethical dilemmas faced by patients and medical professionals [1][2][20]. Group 1: Fraud Scheme Details - The fraud scheme involved pharmaceutical representatives, private hospitals, and dispensing companies colluding to induce patients to falsely claim medical expenses for hemophilia medications, leading to significant financial losses for the healthcare system [1][13][15]. - Patients were offered incentives, such as a 4% rebate on medication purchases, which encouraged them to participate in the fraudulent activities [8][9][12]. - The scheme exploited the reimbursement policies that limited adult hemophilia patients to medication use only during bleeding episodes, creating a loophole that allowed for excessive and unnecessary prescriptions [2][20][21]. Group 2: Patient Experiences and Impacts - Hemophilia patients, particularly those with severe conditions, relied on medications like recombinant factor VIII to manage their health, often leading to a high frequency of prescriptions [5][9][34]. - The fraudulent practices have resulted in patients facing difficulties in obtaining necessary medications, as hospitals have become more cautious in prescribing due to the legal implications of the fraud cases [33][34]. - The article highlights the emotional and physical toll on patients, who now struggle to access their medications and face stigma associated with the fraud allegations [33][34]. Group 3: Regulatory and Policy Implications - The case has drawn attention to the discrepancies between healthcare policies and the best treatment practices for hemophilia, particularly the need for preventive treatment versus the current reimbursement limitations [2][31]. - Experts argue that the existing healthcare reimbursement policies do not adequately address the needs of hemophilia patients, leading to a conflict between patient care and regulatory compliance [30][31]. - The fraud case has prompted stricter enforcement of healthcare policies, impacting the availability of medications for patients and raising concerns about the future of treatment for hemophilia in the region [33][34].

公告指出，受行业政策持续深化及公司核心产品安佳因 多次降价影响，核心产品销售收入降幅较大， 致使公司整体营业收入较上年同期下降。此外，公司相应加大了前期商业化投入，包括学术推广、组建 销售团队等，销售费用因此在短期内增幅明显，而且公司研发投入继续保持高位，影响当期盈利表现。 近日，神州细胞发布公告称，公司预计2025年归母净亏损5.2亿元至5.8亿元；预计扣非净亏损5.03亿元 至5.63亿元；预计公司2025年度研发投入为8.3亿元到8.7亿元。 ...

证券之星消息，2月2日生物制品板块较上一交易日下跌2.83%，神州细胞领跌。当日上证指数报收于 4015.75，下跌2.48%。深证成指报收于13824.35，下跌2.69%。生物制品板块个股涨跌见下表： 以上内容为证券之星据公开信息整理，由AI算法生成（网信算备310104345710301240019号），不构成投资建议。 从资金流向上来看，当日生物制品板块主力资金净流出6.42亿元，游资资金净流入3.89亿元，散户资金净 流入2.52亿元。生物制品板块个股资金流向见下表： | 代码 | 名称 | 主力净流入(元) | 主力净占比 游资净流入(元) | | 游资净占比 散户净流入 (元) | | 散户净占比 | | --- | --- | --- | --- | --- | --- | --- | --- | | 301207 | 华兰疫苗 | 1967.06万 | 5.06% | -124.16万 | -0.32% | -1842.90万 | -4.74% | | 002880 卫光生物 | | 1473.64万 | 8.15% | 246.89万 | 1.37% | -1720.53万 | -9.52 ...

神州细胞(688520)1月30日晚间披露2025年年度业绩预告，经财务部门初步测算，预计公司2025年年度实现归属于母公司所有者的净利润与上年同期相 比，将出现亏损，实现归属于母公司所有者的净利润-5.8亿元到-5.2亿元；归属于母公司所有者的扣除非经常性损益后的净利润-5.63亿元到-5.03亿元。预 计公司2025年度研发投入8.3亿元到8.7亿元。 本期业绩变化的主要原因为，受行业医保控费政策持续深化及公司核心产品安佳因多次降价影响，核心产品销售收入降幅较大，致使公司整体营业收入较 上年同期下降。为推进报告期内新获批产品的市场准入与渠道建设，公司相应加大了前期商业化投入，包括学术推广、组建销售团队等，销售费用因此在 短期内增幅明显。公司始终坚持多产品管线持续有序推进的研发策略，多个在研项目报告期内先后进入关键的确证性临床试验阶段，研发投入继续保持高 位，影响当期盈利表现。 编辑吴怡漪责编朱峰校审梁荣高 二级市场上，2025年7月中旬以来，神州细胞股价大幅回调，1月30日跌3.24%，收报41.84元/股，创调整以来新低，半年间跌幅逾50%。 ↓↓↓ 神州细胞是一家创新型生物制药公司，专注于恶性肿瘤、自 ...

（二）业绩预告情况 1．经财务部门初步测算，预计公司2025年年度实现归属于母公司所有者的净利润与上年同期相比，将 出现亏损，实现归属于母公司所有者的净利润-58,000.00万元到-52,000.00万元。 2．归属于母公司所有者的扣除非经常性损益后的净利润-56,300.00万元到-50,300.00万元。 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述或者重大遗漏，并对其内容 的真实性、准确性和完整性依法承担法律责任。 一、本期业绩预告情况 （一）业绩预告期间 2025年1月1日至2025年12月31日。 （二）为推进报告期内新获批产品的市场准入与渠道建设，公司相应加大了前期商业化投入，包括学术 推广、组建销售团队等，销售费用因此在短期内增幅明显。 （三）公司始终坚持多产品管线持续有序推进的研发策略，多个在研项目报告期内先后进入关键的确证 性临床试验阶段，研发投入继续保持高位，影响当期盈利表现。 四、风险提示 3．预计公司2025年度研发投入83,000万元到87,000万元。 （三）以上业绩预告数据仅为初步核算数据，未经注册会计师审计。 二、上年同期业绩情况和财务状况 （一）利润总 ...

证券代码：688520 证券简称：神州细胞 公告编号：2026-002 一、本期业绩预告情况 （一）业绩预告期间 2025年1月1日至2025年12月31日。 （二）业绩预告情况 1．经财务部门初步测算，预计公司2025年年度实现归属于母公司所有者的净利润与上年同期相比，将 出现亏损，实现归属于母公司所有者的净利润-58,000.00万元到-52,000.00万元。 2．归属于母公司所有者的扣除非经常性损益后的净利润-56,300.00万元到-50,300.00万元。 3．预计公司2025年度研发投入83,000万元到87,000万元。 北京神州细胞生物技术集团股份公司 2025年年度业绩预告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述或者重大遗漏，并对其内容 的真实性、准确性和完整性依法承担法律责任。 三、本期业绩变化的主要原因 （一）报告期内，受行业医保控费政策持续深化及公司核心产品安佳因? 多次降价影响，核心产品销售 收入降幅较大，致使公司整体营业收入较上年同期下降。 （二）为推进报告期内新获批产品的市场准入与渠道建设，公司相应加大了前期商业化投入，包括学术 推广、组建销售团队等 ...

每经AI快讯，神州细胞1月30日晚间发布业绩预告，预计公司2025年年度实现归属于母公司所有者的净 利润与上年同期相比，将出现亏损，实现归属于母公司所有者的净利润-5.8亿元到-5.2亿元。业绩变动 主要原因是，报告期内，受行业医保控费政策持续深化及公司核心产品安佳因®多次降价影响，核心产 品销售收入降幅较大，致使公司整体营业收入较上年同期下降。为推进报告期内新获批产品的市场准入 与渠道建设，公司相应加大了前期商业化投入，包括学术推广、组建销售团队等，销售费用因此在短期 内增幅明显。公司始终坚持多产品管线持续有序推进的研发策略，多个在研项目报告期内先后进入关键 的确证性临床试验阶段，研发投入继续保持高位，影响当期盈利表现。 每经头条（nbdtoutiao）——核电建设热潮下，设备厂忙到"飞起"！订单已排至2028年，员工三班倒， 产线24小时不停 （记者 曾健辉） 免责声明：本文内容与数据仅供参考，不构成投资建议，使用前请核实。据此操作，风险自担。 每日经济新闻 ...